A retrospective study on the significance of liver biopsy and hepatitis b surface antigen in chronic hepatitis B infection

Medicine (United States)

Volumn 95, Issue 8, 2016, Pages

  Zeng, Da Wu ^a   Zhang, Jie Min ^a   Liu, Yu Rui ^a   Dong, Jing ^a   Jiang, Jia Ji ^a   Zhu, Yue Yong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN;

ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNE CLEARANCE; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL TOLERANCE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEROLOGY; BIOPSY; BLOOD; CHRONIC HEPATITIS B; FOLLOW UP; GENETICS; GENOTYPING TECHNIQUE; HEPATITIS B VIRUS; LIVER; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS; BIOPSY; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPING TECHNIQUES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84962611403     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002503     Document Type: Article

References (33)

1. Lok AS. The maze of treatments for hepatitis B. N Engl J Med. 2005;352:2743-2746.
2. Pan YF, Qin T, Feng L, et al. Expression profile of altered long non-coDing RNAs in patients with HBV-associated hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2013;33:96-101.
3. Vildozola Gonzales H, Salinas JL. Natural history of chronic hepatitis B virus infection. Rev Gastroenterol Peru. 2009;29:147-157.
4. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol. 1997;12:S218-222.
5. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl):1100-1107.
6. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos (t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48:13-21.
7. Ganji A, Esmaeilzadeh A, Ghafarzadegan K, et al. Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV. Hepat Mon. 2011;11:342-345.
8. Gupta E, Kumar A, Choudhary A, et al. Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study. Indian J Med Microbiol. 2012;30:150-154.
9. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508-513.
10. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514-522.
11. Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S61-S71.
12. Kitamura M. The characteristic findings of chronic hepatitis B in liver biopsy specimens. Nihon Rinsho. 1995;53(Suppl Pt 2):547-551.
13. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158.
14. Zeng DW, Liu YR, Zhang JM, et al. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942.
15. Karimi A, Salimzadeh L, Bagheri N. Hepatitis B virus genotyping among chronic hepatitis B individuals with resistance to Lamivudine in shahrekord, iran. Jundishapur J Microbiol. 2014;7:e10196.
16. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561.
17. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341; quiz 1286.
18. Evans AA, London WT, Gish RG, et al. Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther. 2013;18:229-235.
19. Poddar U, Yachha SK, Agarwal J, et al. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? J Viral Hepat. 2013;20:311-316.
20. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075.
21. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
22. Zhuang H. Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi. 2012;20:427-429.
23. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
24. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283.
25. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610-1614.
26. Kennedy PT, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143:637-645.
27. Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015;12:258-263.
28. Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760-767.
29. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-592.
30. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750-1758.
31. Li W, Zhao J, Zou Z, et al. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. PLoS One. 2014;9:e89046.
32. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221-1228.
33. Malmstrom S, Larsson SB, Hannoun C, et al. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load-down-regulated transcription of PgRNA has limited impact. PLoS One. 2012;7:e36349.